Invex Therapeutics Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

34.45

EPS

—

Div Yield, %

—

Shrs. gr., 5y

6.15%

Rev. gr., 5y

Revenues

229k

-81.10%

Net income

-477k

L-70.96%

CFO

-653k

L-73.30%

Dividend

Dec 08, 20230.1863 AUD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.

URL

https://invextherapeutics.com/

IPO date

Jul 05, 2019

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2025‑06	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT